EPAX® Cetoleic 2040 is a new oil offering the highest concentration of long-chain mono-unsaturated fatty acids (LC-MUFAs) Omega-9 Gondoic acid and Omega-11 Cetoleic acid on the market. Produced from sustainably sourced North Atlantic fish species using a newly patented concentration technology, it is specifically designed to maximize LC-MUFAs while minimizing long-chain polyunsaturated fatty acids (LC-PUFAs), including Omega-3.

The result is a precision marine lipid ingredient that enables focused investigation of LC-MUFA biology with minimal interference from EPA and DHA Omega-3s.

Designed for LC-MUFA Research

EPAX Cetoleic 2040 has become the preferred oil for a growing number of preclinical and clinical studies investigating the health effects of Cetoleic acid and related LC-MUFAs. The low levels of Omega-3 fatty acids enable the researchers to specifically study the biological activity of LC-MUFAs with confidence.

This precision approach has helped establish new insights into the role of marine LC-MUFAs in metabolic health, inflammation and lipid metabolism.

Emerging Science

Several preclinical and clinical studies demonstrate the beneficial effects of EPAX Cetoleic 2040 on cholesterol and LDL-cholesterol. A recently published human clinical study showed that 8 weeks of supplementation resulted in a statistically significant reduction in LDL cholesterol of 7% in overweight or obese subjects [1].

In addition, preclinical studies demonstrate that EPAX Cetoleic 2040 has strong anti-inflammatory effects, particularly within white adipose tissue [2]. This is especially relevant in the case of excess visceral fat, the fat stored around internal organs, which is closely associated with systemic inflammation, impaired metabolic health and increased cardiovascular risk.

A Unique Mechanism

Unlike Omega-3 fatty acids, Cetoleic acid shows a strong tendency to accumulate in adipose tissue [3]. This distinct tissue distribution is believed to contribute to its biological effects, including reduced inflammation within fat tissue and improvements in metabolic regulation, including cholesterol metabolism [4].

Combining the Cetoleic acid characteristics of fat tissue accumulation together with strong anti-inflammatory effects supports a role of LCMUFAs in maintaining healthy adipose tissue.  

Part of the NovusLipid™ Platform

EPAX Cetoleic 2040 joins the growing NovusLipid™ portfolio of marine lipid innovations.

EPAX® Omega 3-9-11 combines cetoleic acid with substantial levels of EPA and DHA, offering a holistic marine lipid solution for metabolic health and skin applications.

EPAX® Cetoleic 2040 provides a precision LC-MUFA platform for researchers and formulators seeking to explore the specific biological potential of marine Omega-9 and Omega-11 fatty acids.

‍

References

1. Hansen, K., et al., Supplementation with a cetoleic acid concentrate decreased the serum LDL-cholesterol concentration in healthy adults with overweight or obesity. A randomised double-blind controlled clinical trial. Br J Nutr, 2026: p. 1-29.

2. Hansen, A., et al., Intake of a cetoleic acid concentrate lowered concentrations of markers of inflammation and macrophage infiltration but did probably not increase EPA biosynthesis in male obese Zucker fa/fa rats. Br J Nutr, 2025. 134(11): p. 881-891.

3. Rimmen, E.V., et al., Absorption, accumulation and metabolism of cetoleic acid from dietary herring oil in tissues of diabetic male Zucker Diabetic Sprague Dawley rats. Br J Nutr, 2025: p. 1-24.

4. Yang, Z.H., et al., Long-term dietary supplementation with saury oil attenuates metabolic abnormalities in mice fed a high-fat diet: combined beneficial effect of omega-3 fatty acids and long-chain monounsaturated fatty acids. Lipids Health Dis, 2015. 14: p. 155.

‍